Cellares News and Resources

Cellares, in partnership with Mitsui Fudosan Co., Ltd., has announced plans to open its first Asian regenerative medicine manufacturing facility in Kashiwa-no-ha Smart City, Japan, by 2027. The new site will be part of Mitsui Fudosan’s Mitsui Link Lab, currently

Cellares, an Integrated Development and Manufacturing Organization (IDMO), has entered into a strategic collaboration with the University of Wisconsin School of Medicine and Public Health. The aim is to automate the manufacturing of a CRISPR-edited GD2 CAR-T investigational therapy. The

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has announced that its Cell Shuttle has been granted the Advanced Manufacturing Technology (AMT) designation by the U.S. Food and Drug Administration (FDA). The designation, issued by the Center for Biologics

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded its Technology Adoption Program (TAP) for rese-cel, a CD19-targeting CAR T cell therapy developed by Cabaletta Bio. The program evaluated the feasibility of automating rese-cel’s manufacturing using Cellares’ Cell Shuttle™ platform, a next-generation automated

Cellares, a provider of automated cell therapy manufacturing solutions, has announced a partnership with Sony Corporation to jointly develop advanced flow cytometry-based cell analysis and sorting solutions. The collaboration will incorporate Sony’s CGX10 Cell Isolation System into Cellares’ Cell Shuttle

Cellares, an Integrated Development and Manufacturing Organization (IDMO), has completed the first cGMP Cell Shuttle at its Smart Factory in Bridgewater, New Jersey. This marks a key milestone for the facility, which aims to produce up to 40,000 standard CAR-T

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, has announced that Kite Pharma, a Gilead Company, will evaluate its automated manufacturing platform, the Cell Shuttle. This proof-of-concept evaluation aims to generate